Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hainan Aoruikang Biomedical Technology Co. Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's active prosecution is currently limited to this single matter. This indicates a highly concentrated administrative footprint, with no current activity in other art units or technology areas.
SOPHIA P HIRAKIS is the busiest examiner for the portfolio, with 1 pending office action. This single action constitutes the total pending workload for the company. The alignment of 1 distinct examiner and 1 pending action indicates that all current prosecution is under the review of one person. For a practitioner, this means that the success of the company's current filings in the Biotechnology & Pharmaceuticals sector is dependent on navigating the specific requirements of this examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412178 | EGCG buccal tablet and use thereof | HIRAKIS, SOPHIA P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412178 | EGCG buccal tablet and use thereof | HIRAKIS, SOPHIA P | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18412178 | EGCG buccal tablet and use thereof | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHainan Aoruikang Biomedical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sophia P Hirakis has the most, with 1 of Hainan Aoruikang Biomedical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
